



April 1, 2026

Perseus Proteomics Inc.

Securities Code: 4882 Growth TSE

email: ir@ppmx.com

**Notice Regarding the Grant Award Decision under the FY2026 Medical Research and
Development Promotion Program for the Development of PPMX-T003 for Aggressive NK-Cell
Leukemia**

Perseus Proteomics Inc. hereby announces that it has received a notice of decision for a grant of JPY 100 million under the FY2026 Drug Discovery Support Promotion Program / Practical Development Support Program Prior to Orphan Drug Designation administered by the Japan Agency for Medical Research and Development (AMED).

Aggressive NK-cell leukemia is a rapidly progressing leukemia with a poor prognosis that affects younger and middle-aged patients, including adolescents and young adults (AYA). The disease has a median survival of less than two months and is a refractory disease for which no effective treatment has been established. In addition, because it accounts for only approximately 0.5% of all malignant lymphomas, the small number of cases has substantially limited the development of treatments, creating a need for effective new drugs.

PPMX-T003 targets transferrin receptor 1 (TfR1), which is involved in cellular iron uptake. TfR1 is expressed at extremely high levels in hematopoietic cells, which require more iron than normal cells, and is also frequently expressed at high levels in cancer cells. By binding to TfR1, PPMX-T003 is expected to inhibit iron uptake into cancer cells and thereby suppress their proliferation.

This support program covers expenses related to the conduct of an investigator-initiated clinical trial of PPMX-T003 for aggressive NK-cell leukemia. The Company expects to receive support for a period of up to three fiscal years starting from FY2025, with the grant amount to be determined for each fiscal year.

This subsidy is scheduled to be received in the fiscal year ending March 2027 and will be recorded as Long-term deposits received.

The impact of this matter on the Company's financial results for the current fiscal year is expected to be immaterial.